Tag: Nektar Therapeutics

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

SAN FRANCISCO, July 31, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Thursday, August 7, 2025, after the...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor (ROR) pathways in cancer and...

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of innovative medicines in the...

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis...

SAN FRANCISCO, June 23, 2025 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on development of novel immunology therapies, today announced it...

- A word from our sponsors -

HomeTagsNektar Therapeutics

Huasun Ranked 12th on TIME’s World’s Top GreenTech Companies of 2026, Leaping 22 Places on the Strength of HJT Conviction

Scenic Biotech Joins Michael J. Fox Foundation’s LITE Program to Explore New Disease-Modifying Approach for Parkinson’s Disease

Zoetis Inc. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – ZTS

Tag: Nektar Therapeutics

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

ROR Inhibitors Market Expected to Witness Significant Growth Through 2034 Due to the Rising Oncology Research and Pipeline Advancements | DelveInsight

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis...

Explore

Press Releases

News & Opinion

Living

Others

Follow us